| Literature DB >> 30066822 |
Nonato Mendonça Lott Monteiro1, Karla Emília de Sá Rodrigues1, Paula Vieira Teixeira Vidigal1, Benigna Maria de Oliveira1.
Abstract
OBJECTIVE: To analyze clinical, laboratory and histopathological features and the path to diagnosis establishment and treatment of patients with adrenal carcinoma (AC).Entities:
Mesh:
Substances:
Year: 2018 PMID: 30066822 PMCID: PMC6362376 DOI: 10.1590/1984-0462/;2019;37;1;00002
Source DB: PubMed Journal: Rev Paul Pediatr ISSN: 0103-0582
Demographic characteristics of the study population: 13 patients diagnosed with adrenal carcinoma.
| Characteristic | Median | Min-Max |
|---|---|---|
| n | % | |
| Age upon diagnosis (years) | 2.0 | 1.1-14.8 |
| Time of follow-up (years) | 4.6 | 0.4−10.5 |
| Gender | ||
| Female | 10.0 | 76.9 |
| Male | 3.0 | 23.1 |
| Origin | ||
| Belo Horizonte | 4.0 | 30.8 |
| Minas Gerais countryside | 9.0 | 69.2 |
| Family history of neoplasms | ||
| Yes | 5.0 | 38.5 |
| No | 8.0 | 61.5 |
| Outcome | ||
| Alive and free of disease | 11.0 | 84.6 |
| Obit | 1.0 | 7.7 |
| Lost to follow-up | 1.0 | 7.7 |
Clinical manifestations upon diagnosis of 13 patients with adrenal carcinoma.
| Sign/symptom | n | % |
|---|---|---|
| Terminal hairs appearance | 13 | 100.0 |
| Pubertal progress | 13 | 100.0 |
| Hypercortisolism clinical manifestations | 13 | 100.0 |
| Virilization* | 10 | 100.0 |
| Enlarged clitoris* | 10 | 100.0 |
| Acne | 9 | 69.2 |
| Systemic arterial hypertension | 5 | 38.5 |
| Cushingoid facies | 4 | 30.8 |
| Weight gain | 3 | 23.1 |
| Voice changes | 3 | 23.1 |
| Abdominal pain | 2 | 15.4 |
| Fever | 1 | 7.7 |
| Muscle hypertrophy | 1 | 7.7 |
*Females (n=10).
Preoperative hormonal characteristics of the 13 patients with adrenal carcinoma.
| Patient | Gender | Age upon diagnosis (year/month) | Serum cortisol | Urinary cortisol | DHEA-S | Testosterone | Androstenedione | 17-OH-progesterone | Aldosterone | Serum renin |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 2y3m | N | 0 | I | I | I | I | 0 | 0 |
| 2 | F | 1y | N | 0 | I | I | 0 | 0 | 0 | 0 |
| 3 | F | 1y10m | N | I | I | I | 0 | I | 0 | 0 |
| 4 | M | 1y | N | 0 | I | N | I | I | 0 | 0 |
| 5 | F | 2y | N | 0 | I | I | 0 | I | I | 0 |
| 6 | F | 3y | 0 | 0 | I | I | I | I | 0 | 0 |
| 7 | M | 14y9m | I | I | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | F | 1y6m | N | 0 | I | I | I | I | 0 | 0 |
| 9 | F | 7y6m | I | 0 | I | I | 0 | N | 0 | 0 |
| 10 | F | 13y1m | I | 0 | N | I | I | I | I | 0 |
| 11 | F | 1y5m | N | 0 | I | N | I | I | 0 | 0 |
| 12 | M | 4y10m | N | 0 | I | I | I | 0 | 0 | 0 |
| 13 | F | 1y6m | N | 0 | N | 0 | N | 0 | 0 | 0 |
F: female; M: male; N: normal compared to reference value; 0: not informed; I: increased compared to reference value; DHEA-S: Dehydroepiandrosterone sulfate.
Characterization of the 13 patients diagnosed with adrenal carcinoma as to clinical variables and outcome.
| Age | Patient # | Age upon diagnosis | Staging | Time of follow-up (year/month) | Outcome |
|---|---|---|---|---|---|
| ≤4 years | 2 | 1y | II | 9y9m | AND |
| 4 | 1y | I | 6m | LF | |
| 11 | 1y5m | I | 4y7m | AND | |
| 8 | 1y6m | I | 2y | AND | |
| 13 | 1y6m | I | 8m | AND | |
| 3 | 1y10m | I | 9y9m | AND | |
| 5 | 2y | I | 7y11m | AND | |
| 1 | 2y3m | I | 10y6m | AND | |
| 6 | 3y | I | 7y9m | AND | |
| >4 years | 12 | 4y10m | I | 9m | AND |
| 9 | 7y6m | III | 4y9m | AND | |
| 10 | 13y1m | I | 4y9m | AND | |
| 7 | 14y9m | IV | 4m | Obit |
LF: loss to follow-up; AND: alive and free of disease.